FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

October 10, 2017: By Joan McKenna

SparkSpark Therapeutics’ gene therapy candidate for inherited retinal disease will be reviewed Oct. 12 by the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee.

The panel will consider whether to recommend voretigene neparvovec, branded Luxturna, for the treatment of patients with vision loss due to retinal dystrophy caused by flaws in the RPE65 gene.

Spark says the gene mutation breaks the visual cycle of light activating photoreceptors, resulting in progressive vision loss and often near blindness.

The FDA has granted orphan drug, breakthrough therapy, and rare pediatric disease designations for voretigene neparvovec, a one-time treatment.

Spark estimates that disease affects an estimated 1 thousand to 3 thousand patients in the US.

Philadelphia-based Spark, founded in March 2013, now has a workforce of 300 industry professionals and has secured $1 billion in financing. It has a pipeline of eight investigational gene therapies. Luxturna is its lead candidate.

The panel meeting will run 8:30 to 5 p.m. Oct. 12 at the FDA’s White Oak Campus in Silver Spring, Maryland.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022